LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 1.58M | $1.81B | n/a | n/a |
| Q2 2026 | 193 | +4 | 672.02M | $805.16B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | n/a |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | n/a |
| Q2 2024 | 22 | n/a | 112.43M | $101.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 784.94K | -21.7% | $908.23M | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 2 | Ninety One UK Ltd | 344.97K | -39.5% | $399.16M | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 243.32K | +26.5% | $280.10M | 0.7% | ▲ Add | 4 | SEC ↗ |
| 4 | Wealth Enhancement Advisory… | 204.61K | +11.4% | $218.04M | 0.3% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,323 holders, 762.84M shares, $674.93B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.50K sh · $7.64M
Officer · 2.00K sh · $2.37M
Officer · 5.00K sh · $5.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology